KALA BIO, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KALA research report →
Range $1.5 – $35
Price Chart
About the company
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs).
- CEO
- Avi Minkowitz
- IPO
- 2017
- Employees
- 6
- HQ
- Arlington, MA, US
Get TickerSpark's AI analysis on KALA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.74M
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -222.32%
- ROIC
- -232.05%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-39,161,000
- Net Income
- $-26,980,000+29.9%
- EPS
- $-4965.00+67.4%
- OCF Growth
- -8.9%
- FCF Growth
- -8.1%
- 52W High
- $2865.00
- 52W Low
- $2.65
- 50D MA
- $8.94
- 200D MA
- $144.82
- Beta
- -2.21
- RSI (14)
- 19
- Avg Volume
- 52.28K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kala exited the commercial business, monetized EYSUVIS/INVELTYS, and is now focused on advancing KPI-012 with cash runway into the second quarter of 2024.· August 11, 2022
- Sold EYSUVIS and INVELTYS to Alcon in July and received $65 million upfront/inventory consideration, with up to $325 million more tied to commercial milestones.
- Company is now prioritizing R&D, especially KPI-012 in PCED, with a Phase II/III trial planned for the fourth quarter of 2022 and top-line results expected in the first quarter of 2024.
- Management is also evaluating KPI-012 for partial LSCD and Sjogren’s ocular disease, plus potential retinal indications.
- Cash at June 30, 2022 was $44.6 million, and management said cash plus Alcon proceeds and expense cuts should fund operations into Q2 2024.
- Operating expenses are being sharply reduced after the Alcon transaction, with non-GAAP operating expenses planned down more than 50% versus the first half of 2022 and 60% to 70% versus full-year 2021.
Kala reported cash and cash equivalents of $44.6 million at June 30, 2022, versus $92.1 million at December 31, 2021, with the decline mainly due to operating cash use. SG&A was $22.7 million in Q2 2022 versus $27.0 million in Q1 2022, and non-GAAP SG&A was $20.4 million versus $24.7 million, primarily from lower employee-related spending. R&D expense was $4.5 million in Q2 2022, flat with Q1 2022. The company said it received $65 million from Alcon at closing, including a $60 million upfront payment and $5 million for inventory, and is eligible for up to $325 million in commercial-based milestone payments. Forward-looking guidance: management expects cash resources plus Alcon proceeds and expense reductions to fund operations into the second quarter of 2024, beyond the KPI-012 Phase II/III readout; KPI-012 Phase II/III initiation is targeted for Q4 2022, with top-line results in Q1 2024.
Mark Iwicki framed the quarter as a transition from a commercial-stage company back to an R&D company focused on serious eye diseases. He emphasized that selling EYSUVIS and INVELTYS to Alcon was the right move for patients and said Alcon is well positioned to expand the products' reach. He sounded constructive on the pipeline, highlighting KPI-012 as the lead program and pointing to additional opportunities in rare ocular diseases and potentially retinal indications.
Mary Reumuth focused on liquidity, cost actions, and runway. She said cash was $44.6 million at quarter-end, not including the early-July Alcon proceeds, and that the company expects to fund operations into Q2 2024. She also detailed expense reductions, noting SG&A fell to $22.7 million from $27.0 million sequentially, non-GAAP SG&A fell to $20.4 million from $24.7 million, and the company plans to cut non-GAAP operating expenses by more than 50% versus the first half of 2022 and by 60% to 70% versus full-year 2021.
Analysts focused on how far along the LSCD and Sjogren’s programs are, whether Kala needs Phase II/III data before designing the second pivotal PCED study, and whether the company may need to raise capital. Management said LSCD and Sjogren’s are still in development-pathway analysis and protocol design work, so they are not ready for clinic yet, though they can reuse CMC and clinical supplies from the PCED program. On the PCED program, management said they will prepare before the top-line readout but need those data to finalize the second pivotal trial’s dose and duration. On cash, they reiterated runway into Q2 2024.
The company now has a simpler structure and more cash flexibility after the Alcon deal, plus a lower-cost operating model. Management expressed confidence in KPI-012’s potential, citing prior evidence of benefit in 8 evaluable PCED patients with complete healing in 6 of 8 and saying the program addresses a large unmet need.
The key near-term risk is execution on KPI-012, since the second pivotal trial design depends on top-line results from the first Phase II/III study. Management also acknowledged that LSCD and Sjogren’s are still in earlier-stage planning, so those opportunities are not ready for the clinic yet, and the company still depends on successful development progress to justify the pipeline transition.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 644.66K
- Float Shares
- 642.71K
of shares held by institutions
14 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 220.62K | 0 |
| Geode Capital Management, LLC | 173.95K | ▲ 28.80K |
| Vanguard Fiduciary Trust Co | 101.40K | 0 |
| Vanguard Group Inc | 91.01K | ▼ 119.82K |
| State Street Corp | 88.57K | 0 |
| Renaissance Technologies LLC | 81.10K | ▲ 81.10K |
| Blackrock, Inc. | 71.45K | ▼ 96 |
| Northern Trust Corp | 41.61K | ▲ 30.08K |
| Goldman Sachs Group Inc | 10.92K | ▼ 3.13K |
| Ubs Group AG | 1.34K | ▼ 7.71K |
| Tower Research Capital LLC (Trc) | 616 | ▲ 616 |
| Morgan Stanley | 124 | ▲ 96 |
Held by 7 ETFs
Biggest fund positions in KALA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 30, 26 | Purdy Brendan P. | other | 0 |
| Jan 30, 26 | Posen Hillel D. | other | 0 |
| Jan 30, 26 | Minkowitz Avraham | other | 0 |
| Jan 30, 26 | Colman Yonatan C. | other | 0 |
| Jan 30, 26 | Berger Chaim D. | other | 0 |
| Dec 18, 25 | Lazar David E. | other | 368,614 |
| Nov 25, 25 | OXFORD FINANCE LLC | other | 0 |
| Nov 9, 25 | Lazar David E. | other | 0 |
| Nov 23, 25 | Lazar David E. | other | 0 |
| Nov 24, 25 | Lazar David E. | other | 900,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KALA coverage
Recent articles, reports, and earnings notes.
No research on KALA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KALA report →KALA BIO Announces Reverse Stock Split
newsfilecorp.com · Nov 12
KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
newsfilecorp.com · Nov 9
KALA BIO, Inc. (NASDAQ:KALA) Stock Short Interest Report for September
defenseworld.net · Oct 12
KALA BIO (NASDAQ:KALA) Stock Falls 0.9% – Time to Sell?
defenseworld.net · Oct 11
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
newsfilecorp.com · Sep 29
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
globenewswire.com · Sep 24
KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of “Reduce” by Brokerages
defenseworld.net · Sep 18
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
globenewswire.com · Sep 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.